Evidence map›Paper›PMID 26320890›Full record

ArticleJournal of the American Society of Hypertension : JASH2015

Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial.

Carolyn H Still, Timothy E Craven, Barry I Freedman, Peter N Van Buren, Kaycee M Sink, Anthony A Killeen, Jeffrey T Bates, Alberta Bee, Gabriel Contreras, Suzanne Oparil and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Hypertension : JASH, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Carolyn H StillDivision of Nephrology and Hypertension, Clinical Hypertension Program, University Hospitals Case Medical Center, Cleveland, OH, USA; Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, OH, USA. Electronic address: cwh11@case.edu.
Timothy E CravenDepartment of Biostatistics, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Barry I FreedmanDepartment of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Peter N Van BurenDivision of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kaycee M SinkWake Forest School of Medicine, Section on Geriatrics and Gerontology, Winston-Salem, NC, USA.
Anthony A KilleenDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Jeffrey T BatesMichael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA.
Alberta BeeDivision of Nephrology and Hypertension, Clinical Hypertension Program, University Hospitals Case Medical Center, Cleveland, OH, USA.
Gabriel ContrerasNephrology Department, University of Miami Miller School of Medicine, Miami, FL, USA.
Suzanne OparilDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Carolyn M PedleyDepartment of Internal Medicine, Wake Forest School of Medicine, Wake Forest Baptist Health, Winston-Salem, NC, USA.
Barry M WallMemphis Veterans Affairs Medical Center, Memphis, TN, USA.
Suzanne WhiteDepartment of Internal Medicine, Northeast Ohio Neighborhood Health Services, Inc, Cleveland, OH, USA.
Delia M WoodsDepartment of Medicine, Nephrology Division, Vanderbilt University, Nashville, TN, USA.
Carlos J RodriguezDepartment of Epidemiology and Prevention, Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Jackson T WrightDivision of Nephrology and Hypertension, Clinical Hypertension Program, University Hospitals Case Medical Center, Cleveland, OH, USA; Department of Nephrology and Hypertension, Case Western Reserve University, School of Medicine, Cleveland, OH, USA.
SPRINT Study Research Group

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Tufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025771 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CENTER, DAVID M. · 2008 to 2011
$17.6M
TUFTS CLINICAL AND TRANSLATION SCIENCE INSTITUTE (UL1): BPCAUL1RR025752 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
$17.6M
NCATS NIH HHS 9U54TR000017-06NCATS NIH HHS UL1 TR000002NCATS NIH HHS UL1TR000002NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1TR000003NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1TR000005NCATS NIH HHS UL1 TR000050NCATS NIH HHS UL1TR000050NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1TR000064NCATS NIH HHS UL1 TR000073NCATS NIH HHS UL1TR000073NCATS NIH HHS UL1 TR000075NCATS NIH HHS UL1TR000075NCATS NIH HHS UL1 TR000093NCATS NIH HHS UL1TR000093NCATS NIH HHS UL1 TR000105NCATS NIH HHS UL1TR000105-05NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1TR000445NCATS NIH HHS UL1 TR001064NCATS NIH HHS UL1TR001064NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR001427NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1RR024134NCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1RR025752NCRR NIH HHS UL1 RR025755NCRR NIH HHS UL1RR025755NCRR NIH HHS UL1 RR025771NCRR NIH HHS UL1RR025771NHLBI NIH HHS HHSN268200900040CNHLBI NIH HHS HHSN268200900046CNHLBI NIH HHS HHSN268200900047CNHLBI NIH HHS HHSN268200900048CNHLBI NIH HHS HHSN268200900049CNHLBI NIH HHS R01 HL104199
6 · The paper itself

Abstract

The Systolic Blood Pressure Intervention Trial (SPRINT) will compare treatment to a systolic blood pressure goal of <120 mm Hg to treatment to the currently recommended goal of <140 mm Hg for effects on incident cardiovascular, renal, and neurologic outcomes including cognitive decline. The objectives of this analysis are to compare baseline characteristics of African American (AA) and non-AA SPRINT participants and explore factors associated with uncontrolled blood pressure (BP) by race. SPRINT enrolled 9361 hypertensive participants aged older than 50 years. This cross-sectional analysis examines sociodemographics, baseline characteristics, and study measures among AAs compared with non-AAs. AAs made up 31% of participants. AAs (compared with non-AAs) were younger and less frequently male, had less education, and were more likely uninsured or covered by Medicaid. In addition, AAs scored lower on the cognitive screening test when compared with non-AAs. Multivariate logistic regression analysis found BP control rates to <140/90 mm Hg were higher for AAs who were male, had higher number of chronic diseases, were on diuretic treatment, and had better medication adherence. SPRINT is well poised to examine the effects of systolic blood pressure targets on clinical outcomes as well as predictors influencing BP control in AAs.

Indexed as

Medication AdherenceRandomized Controlled Trials as TopicAgedAge FactorsAntihypertensive AgentsBlack or African AmericanBlack PeopleBlood PressureBody Mass IndexChronic DiseaseCross-Sectional StudiesEducational StatusFemaleHumansHypertensionMaleAntihypertensive AgentsblacksCardiovascular diseaseclinical trialshypertensionSPRINT

Identifiers

PMID26320890
PMCPMC4573272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.